Endogenous / BiologyEndogenousHuman-supportedUpdated 2026-04-24

Peptide reference file

CGRP

Trending #28 in Endogenous8.4k searches/moProven

CGRP is an endogenous neuropeptide involved in vascular and migraine-related signaling and is central to a major therapeutic drug class.

Current readout: human-supported evidence, endogenous status, endogenous approval state, human evidence appears in the current trail, registered trials are linked, and 3 linked sources in the seed trail.

PubChem CID 168324612 | 20423 PubMed results | 213 trial records | 0 DailyMed labels | 0 Drugs@FDA applications

CGRP is mostly discussed because it matters because it shows how core peptide biology can lead to large modern therapeutic categories.

The public claim is straightforward: It matters because it shows how core peptide biology can lead to large modern therapeutic categories. Strong translational human biology relevance.

In plain language, cGRP is an endogenous neuropeptide involved in vascular and migraine-related signaling and is central to a major therapeutic drug class.

Human-supportedEndogenous
NeuropeptideMigraine biologyVascular signaling

Aliases: Calcitonin gene-related peptide

SpecimenCGRP specimen
CCCCHHHHHHHNOS
Formula
C163H273N51O49S2
Mass
3795.4
Evidence
Human-supported
Elements
5

Most commonly discussed in relation to Neuropeptide, Migraine biology, Vascular signaling.

What CGRP is

CGRP is an endogenous neuropeptide involved in vascular and migraine-related signaling and is central to a major therapeutic drug class.

CGRP is grouped under Endogenous / Biology / Approved / Clinical on PeptideFactCheck because it matters because it shows how core peptide biology can lead to large modern therapeutic categories.

The useful starting point is to separate the molecule itself from the internet story around it. It matters because it shows how core peptide biology can lead to large modern therapeutic categories.

Why people keep looking it up

It matters because it shows how core peptide biology can lead to large modern therapeutic categories.

CGRP is an endogenous neuropeptide involved in vascular and migraine-related signaling and is central to a major therapeutic drug class.

CGRP tends to stay in the conversation because it touches a familiar public theme: neuropeptide, migraine biology, and vascular signaling. That makes it easy for the claim to travel faster than the evidence.

What the evidence can support right now

Strong translational human biology relevance.

Human biology and therapeutic relevance are both strong.

Mechanistic support in migraine and vascular signaling is substantial.

Why this page carries the current tier: Strong translational human biology relevance.

The current seed trail for CGRP is pulling from 2 databases sources and 1 literature source.

Safety, limits, and regulatory context

This entry is mainly about the biology target, not a DIY peptide-use story.

CGRP itself is tracked as endogenous biology rather than a branded peptide medicine.

Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for CGRP. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.

Molecular and identifier data

The current PubChem match for CGRP is CID 168324612. That gives the page a source-backed chemistry record rather than a placeholder identifier block.

PubChem CID
168324612
Formula
C163H273N51O49S2
Molecular weight
3795.4
InChIKey
JAPBQZADVRUIIO-UHFFFAOYSA-N

Matched synonyms include CGRP.

Open PubChem record

Clinical trial snapshot

The current ClinicalTrials.gov intervention query for CGRP returns 213 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.

Literature snapshot

The current PubMed query for CGRP returns 20423 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.

Source trail

Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.

Safety noteThis content is educational only and does not replace medical advice. Peptide use may carry risks and should be discussed with a qualified medical professional.